Dr. Epperly joined VBL in 2017 and is an oncology expert with deep U.S. experience in drug development, strategy, commercialization and operations. Prior to joining VBL, she spent seven years at Bristol-Myers Squibb (BMS), where she delivered results across diverse roles spanning marketing, M&A, strategic operations and medical strategy in the U.S. Immuno-Oncology Business. Prior to joining BMS, she was a member of the Global Healthcare Investment Research team at Goldman Sachs, based in London. Dr. Epperly holds a dual graduate degree, an M.D. and Masters of Public Health from the University of North Carolina at Chapel Hill. She completed her medical training at the University of North Carolina Hospitals with the Department of Pediatrics. She also earned a Distinguished B.A. from the University of Virginia where she studied biochemistry and biology. Prior to medical school she conducted biomedical research in Experimental Immunology on checkpoint inhibition and tumor suppressor genes in the National Cancer Institute, National Institutes of Health.

 drug development